



# NEOPHARMA TECHNOLOGIES LTD

M E D I C A L   D E V I C E   A N D   T E C H N O L O G Y   C O M P A N Y

INFORMATION MEMORANDUM  
SEPTEMBER 2021



# INFORMATION MEMORANDUM



## OFFER AND ISSUE DATES



This Information  
Memorandum is to raise  
\$850,000 AUD.



Neopharma  
Technologies Limited  
(‘Neopharma’ or ‘the  
company’) will issue up  
to 5,667,000 shares  
at a price of 15c/share.



This Information  
Memorandum is dated 12th  
of September 2021.

# LETTER FROM THE CHAIRMAN



Dear Investor,

On behalf of the Company, I am pleased to invite you to invest in Neopharma Technologies Ltd (NTL), which has recently been named one of the Top 100 Healthcare Technology companies of 2021 globally.

Our patented, trademarked and world-leading drugs-of-abuse testing technology takes the physical needs of mandatory drug testing into the digital age of advanced data collection and management to deliver certainty with complete chain-of-custody and the significant increases in productivity and accuracy that comes with digitising a previously manual process.

**TamperLoks DataVault** is our Drugs-of-Abuse testing solution and is poised for full commercialisation in the Australian Mining Industry this year.

While the pandemic has affected many industry sectors, other sectors such as Mining and Oil & Gas, have not only stayed open through the pandemic, but have increased workplace testing to include not only drug testing but also Covid-19 testing.

Capitalising on this, NTL has partnered with MD Solutions to distribute our Drugs-Of-Abuse testing solution in Australia. They are an established supplier of Medical Devices in Australia for over 29 years with strategic partners not only embedded in the Mining and Oil & Gas industries but with clients across many other key industry verticals including, Transportation, Hospitals and Police. With their expertise and belief in our product, MD Solutions have underwritten and managed the TGA Certification process, and have begun direct sales and marketing activity, which is being well received.

Following consultation with the Mining Industry the NTL team, working closely with MD Solutions made a major breakthrough to expand our service offering to not only to include drug testing, but to provide a **Safe Workplace Best Practice** solution for controlled workplaces. It utilises our DataVault IT platform and smart phone App to streamline site access, ensuring workers are Drug and Covid-19 free with a fraction of the current administrative time and cost.

Neopharma's Safe Workplace Best Practice solution is a disruptive game changer that we believe will lead to its rollout across a range of Australian industry verticals currently being serviced by MD Solutions, beginning with Mining and then in other industries including Oil & Gas, Transportation, Hospitals and Police.

# LETTER FROM THE CHAIRMAN



Global markets also provide significant upside potential for the growth of NTL. While the rollout of TamperLoks DataVault across Indonesian Universities and the Malaysian police force is temporarily on hold due to Covid-19, these two projects will go ahead in 2022 and represent a sales pipeline of 3 million units. Additionally we have engaged Malaysia Distributor, Cekap Technical Services, to focus solely on the Oil & Gas industry there.

Further to this we are in current discussions to licence TamperLoks DataVault with established distributors in both Europe and the Americas.

NTL is also working with Oracle to roll out DataVault as an additional service offering to their existing clients that already have their own in-house drug testing programs.

With the company's lean operational structure, low overheads and strategic growth strategy, Neopharma is poised to become a leader in the global Drugs-of-Abuse testing market estimated to be worth \$6 Billion USD currently and growing at 17.1% CAGR to reach \$13.5 Billion USD annually by 2027.

The board of Neopharma Technologies Ltd are committed to maximising investor returns by achieving strong growth in its sales pipeline warranting a listing on the ASX based on a revenue multiple. With a low operational breakeven of only 300,000 TamperLoks unit sales per annum and a strategy of outsourcing manufacturing and distribution, the board is targeting a mid-2022 ASX listing and also looking to implement significant annual dividends.

We are raising up to \$850,000 AUD under this Information Memorandum to expand our company's operations and commercialise our innovative products and services globally.

You are invited to join our award winning Healthcare Technology company at this early-stage, and share our journey and successes. I encourage you to read this Information Memorandum carefully and in full, and if you would like to discuss the opportunity further, please let me know via the OnMarket platform.

We look forward to welcoming you as a stakeholder in Neopharma Technologies Ltd.

Yours sincerely,

Marcus L'Estrange

Executive Chairman



# GLOBAL PATENTED & TRADEMARKED

Drugs-of-Abuse testing  
device TamperLoks &  
Enterprise Resource  
Management Platform  
DataVault

## CERTIFIED APPROVED & AWARD WINNING

- ✓ ISO 13485 Certified
- ✓ USFDA approved drug testing strips
- ✓ Medical Device Authority Malaysia & Indonesia approved
- ✓ TGA approval (pending)
- ✓ Free Sale Agreement USA, Australia, Malaysia, Indonesia, Phillipines & Mexico
- ✓ Neopharma Technologies Top 100 Healthcare Technology Company 2021  
<https://thehealthcaretechnologyreport.com/the-top-100-healthcare-technology-companies-of-2021>

## SMART BUSINESS MODEL

- ✓ Global Protected Intellectual Property
- ✓ Low-cost unit economics
- ✓ Lean operational overheads
- ✓ Secured manufacturer & investor in Malaysia Guppy Plastics
- ✓ Strong commercialisation distribution path with MD Solutions Australasia; Cekap Malaysia; VSD Malaysia; PT Satya Abadi Pharma Indonesia; Apollo Biotech USA & Europe.

Key Global Industry Verticals:

**Growing  
17.1%  
Annually**  
Global Drugs of Abuse  
Testing Market

**TAMPER**  
THE  
UNDENIABLE  
TRUTH  
**LOKS®**




**TamperLoks DataVault  
2min Video :**

<https://www.youtube.com/watch?v=4cdeJKUw2e8>



**The Top 100  
Healthcare Technology  
Companies of 2021**



**\$6B USD**  
Global Drugs of Abuse Testing  
Market Value 2021.

**\$13.5B USD**  
Projected Market Value by  
2027

# CORPORATE SNAPSHOT




## BACKGROUND

Strategy: To be the global leader in drugs-of-abuse early intervention, through reliable testing, management and rehabilitation.

**CORPORATE ACTIVITY:** Unsolicited asset purchase agreements received from separate US based private equity funds in August 2019 and September 2020 for a consideration of \$16,000,000 USD. Neopharma did not proceed with these transactions for the sale of its assets and instead continues to commercialise the assets globally.

## CORPORATE INFORMATION SEPTEMBER 2021

Share issue price	\$0.15
Shares on issue	44,898,798
<b>Market capitalisation</b>	<b>\$6,734,819 AUD</b>
Shareholders	68



# CORPORATE GROUP STRUCTURE



## Neopharma Technologies Limited (Neopharma)

Group head company. Holder of TamperLoks intellectual property.

Australian public company.

## Neopharma Technologies Sdn Bhd

Manufacturing and licensing entity. Malaysian private company.

## Firmitas Global Pty Ltd

DataVault assets and related intellectual property. Australian private company.



100%

100%

Neopharma Technologies Sdn Bhd

Firmitas Global Pty Ltd

# INDUSTRY OVERVIEW



## Global Drug Testing Market Forecast


“The global drug screening market was valued at USD 3.83 Billion in 2019 and is projected to reach USD 13.56 Billion by 2027, at a CAGR of 17.1% during the forecast period.”




The rising usage of advanced technologies in developing economies is further opening up lucrative growth opportunities for players in the market. Development and adoption of new methods for drug screening are expected to fuel market growth in the next few years.



The rapid testing devices segment held the largest market share in 2019, owing to several advantages related to use and adoption of these devices. Tests can be performed on candidates in resource-limited settings using these devices and results are obtained rapidly. The tests are also more cost-effective as well as highly reliable.



The urine testing devices segment dominated other product and service segments in the drug screening market in 2019. Urine tests are painless and can be used to easily detect presence of any illegal drugs or prescription medicines. These devices can also help doctors to understand potential drug abuse issues.



The Asia Pacific market revenue is expected to expand at the highest CAGR as compared to that of other regions during the forecast period, primarily due to high demand from India and China. Development of advanced drugs and increase in the number of drug addicts are likely to boost growth of the market in the region during the forecast period.

# INDUSTRY OVERVIEW

## Market Drivers


- ✓ Increasing consumption of illicit drugs creating demand for drugs-of-abuse tests.
- ✓ High demand for drugs-of-abuse testing screening products from law enforcement agencies.
- ✓ Rising demand for workplace drug screening tests from employers due to increased awareness on the effects of drug abuse on productivity and safety of employees.
- ✓ Government initiatives for creating awareness about illicit drug consumption among students and young adults.
- ✓ Increase in the number of private and public clinical laboratories offering drug abuse testing services.
- ✓ Prescription drug abuse, the legalisation of marijuana and other previously illegal drugs.





# KEY GLOBAL INDUSTRY VERTICALS

- ✓ Mining
- ✓ Oil & Gas
- ✓ Building & Construction
- ✓ Transportation – Air, Land & Sea
- ✓ Pre-Employment
- ✓ Police
- ✓ Military
- ✓ Prisons
- ✓ Border Security
- ✓ Education – Private Universities
- ✓ Hospitals
- ✓ Professional Sports






# TAMPERLOKS DATAVAULT



TamperLoks DataVault drug testing solution is an end-to-end drugs-of-abuse testing and management system.

## Summary

- TamperLoks DataVault is a holistic drugs-of-abuse testing and management system:
  1. TamperLoks enables a rapid drugs-of-abuse urine test and assigns a unique QR code to the candidate being tested.
  2. DataVault records the testers details and test results through an image of the test strips and the unique QR code, utilising a smart phone DataVault app that passes encrypted data in real time to the DataVault that is hosted either in the cloud or on-premise as per the client's requirements.
  3. Test results images are immediately stored in DataVault and unable to be tampered with or changed.
  4. DataVault has a user friendly dashboard which presents the individual test information and macro data such as location areas of positive tests and the drug.
- Significant advancement in end-to-end drugs-of-abuse testing and management.
- TamperLoks DataVault is a global leader, there is no current comparable hardware and technology pairing in the market globally. As a result Neopharma Technologies has been recognized as a top 100 Global Healthcare Technology Company in 2021.



# TAMPERLOKS - RAPID DRUG TEST DEVICE



World class patented 3-chamber tamperproof drugs-of-abuse urine testing device.

## Summary

- Patented 3-chamber tamperproof drugs-of-abuse urine testing device.
- Patents ensuring asset protection with further expansion into new markets.
- TamperLoks patents granted in Australia, USA, Malaysia, Germany, Spain, France, United Kingdom, Italy, Netherlands.
- USFDA approved drug testing strips.
- Limited human intervention or interpretation, minimising risk of human error.
- Testing does not require the tester to pour, transfer or pipette the urine sample into any other container.
- Test results within 90 seconds.
- Temperature and adulteration strips.
- Low production cost with significant economies of scale opportunities.



TamperLoks Cross Section



TamperLoks Drug test strips view panel.



# TAMPERLOKS - PRODUCT COMPARISON



					
	 TamperLoks	 T-Cup	 Alere owned by Abbott	 Nobel	 E-Z Split owned by Abbott
Number of chambers	3	1	1	2	2
Patented locking lid					
100% Tamperproof					
100% odor and leak proof					
US FDA approved test strips					
Sturdy construction					
Electronic chain of custody					
Downloadable app					
Cloud based reporting					
Customisable reporting					

# DISTRIBUTION AGREEMENTS

**MDSOLUTIONS**  
Outcomes Elevated

Signed 5 year exclusive agreement with MD Solutions for the commercial rollout of Neopharma's TLDV solution for Australasia. As part of the agreement MD Solutions have funded and managed the TGA application. All documentation has been submitted to the TGA and is expected within a month. Significant commercial orders are planned on TGA approval that will have a material impact on Neopharma Technologies current valuation.



Signed distribution agreement with Indonesian Distributor PT Satya Abadi Pharma. Pre-Covid planned 1.5 million P/A purchase order for the Indonesian University's. Commercial order expected 2022 once university students are back on campus.

**Cekap**

Signed distribution agreement with CEKAP technical services for the commercial rollout Neopharma's TLDV solution in the Malaysian Oil & Gas sector.



Signed distribution agreement for the rollout of the Malaysian Police sector. Police trials were scheduled pre-Covid, however due to Covid-19 restrictions they have been put on hold. Malaysia Police anticipate orders of up to 1.5 million Drug tests P/A.



# TAMPERLOKS - MANUFACTURING



## Manufacturing

- All TamperLoks production moulds and production equipment is owned by Neopharma.
- World class manufacturing partner who is a strategic equity investor in Neopharma:
  - Amortisation of new purchased tooling of up to \$75,000 repaid with each unit produced.
  - Fixed cost manufacturing price.
  - Manufacturing partner currently services globally significant business across their 3 international production facilities.
- **Capabilities:**
  - Scalable production, options available to increase up to 100,000 units per month with current hard mould.
  - Intended creation of new hard mould to increase capacity to 250,000 units per month, utilising improvements on the first hard mould.
- **Economies of scale opportunities:**
  - Significant reduction in strip purchase price.
  - Increase the use of automation, robotics and jigs.
  - Materials and production cost reduction through increased output.



TamperLoks cups in production at the Penang manufacturing facility.



# DATAVAULT



Cloud based drugs of abuse testing data management and administration system that enables real time recording of drug test data through QR code, images and locational services.

## Key Points

- Industry leading application and IT platform that links with TamperLoks drug test cups and results.
- Real time test data transferred into secure cloud or on-premise data management system.
- Existing testing methods include hand written results and limited recording of test and test provider data.
- Upfront and recurring revenue with minimal associated costs.
- System design enables interchange from English to multiple languages.
- Hosted by Amazon Web Services.
- DataVault app Available on Google Playstore.
- Test location data cross checked with longitude and latitude of image and test device location.





# DATAVAULT - ERM



DataVault is a complete Enterprise Resource Management Platform that allows for drug test program management and track and trace of the testing cups from Manufacturer through Distribution to Testing to Laboratory to Storage. It enables real-time recording of drug test data and utilises advanced AI and Big Data to produce regional data on drugs-of-abuse.



# DATAVAULT - ERM



DataVault has a user friendly dashboard that can be modified to meet client’s individual requirements.



# DATAVAULT - REPORTS



XY11928827YJ

## DRUG PRESCREENING TEST REPORT



CASE NO : XY11928827YJ

ID REF:

NAME: JANE CITIZEN

ADDRESS: 77 SAMPLE PARADE  
KEW EAST VIC 3102

DOB: 29/07/1983

START DATE: 06/08/2019

END DATE : 06/08/2019

DRIVER LICENCE  
VICTORIA AUSTRALIA  
JANE CITIZEN  
FLAT 10  
77 SAMPLE PARADE  
KEW EAST VIC 3102  
LICENCE NUMBER  
20-05-2019 29-07-1983  
LICENCE TYPE  
CAR  
CONDITIONS  
UNRESTRICTED  
VICROADS  
987654321

ID TYPE: LICENCE

ID NO: 987654321

### TAMPERLOKS DRUG RESULT: **NEGATIVE**

DRUG	STRIP CODE	RESULT	REFERENCE INTERVAL ng/mL
MORPHINE	MOR	NEGATIVE	300
MARIJUANA	THC	NEGATIVE	20
COCAINE	COC	NEGATIVE	150
AMPHETAMINE	AMP	NEGATIVE	500
ECSTASY	MDMA	NEGATIVE	500
BENZODIAZEPINES	BENZO	NEGATIVE	300

### TAMPERLOKS ADULTERANT RESULT: **PASSED**

ADULTERANTS CODE	STRIP CODE	RESULT
OXIDANTS	OXI	PASSED
SPECIFIC GRAVITY	SG	PASSED
ACIDICALKALINE	PH	PASSED
TEMPERATURE	TEMP	PASSED

PAGE 1/2

XY11928827YJ

## DRUG PRESCREENING TEST REPORT



### TAMPERLOKS & TESTER DETAILS

TL SERIAL	955G00006AA	TAMPERING	NONE
TESTER	GAJENDRA RAJ	TL REFERENCE	CHECK COMPLETE
SUPERVISOR	MARCUS L		
DURATION	670 SEC		
LAB	N/A		
AREA	SUBIACO		

### TAMPERLOKS CHAIN OF CUSTODY

CUSTODY HOLDER	ISSUES	OWNERSHIP	REF
TAMPERLOKS INCEPTION	NIL	NEO	SHIPMENT TO PORT ON 05052019
JOHN A - ADMIN	NIL	CAPROCK	CUSTODY TRANSFERRED
THOMAS -SUPERVISOR	NIL	ROCKYCAP	CUSTODY TRANSFERRED
MARCUS L-SUPERVISOR	NIL	ROCKYCAP	CUSTODY TRANSFERRED
GAJENDRA -ENFORCEMENT OFFICER	NIL	ROCKYCAP	TEST START
MARCUS L-SUPERVISOR	NIL	N/A	VERIFIED AND CONFIRMED TEST

### REPORT PRINT

REPORT	CASE
REQUEST	THOMAS
ROLE	SUPERVISOR
DATE	07/08/2019
TIME	1255
AREA	SUBIACO

THIS IS A COMPUTER-GENERATED DOCUMENT. NO SIGNATURE IS REQUIRED.

PAGE 2/2

# TIME IN MOTION STUDY INDONESIA



## Current existing procedures:

5 people required for testing 30 people per hour.

The Bottleneck is in recording information manually.



## With TamperLoks DataVault:

2 people required to test 60 people per hour.

TLDV doubles the testing output while more than halving the human resources required. Saving clients significant time and money.



QR Code and unique identification number

Urine sample test results







# DATAVAULT V1.0 & DATAVAULT V2.0 OPPORTUNITIES

## Opportunities

- DataVault v1.0 was developed exclusively for Neopharma Technologies patented Tamperloks 3-chamber urine testing cup with the use of QR code.
- DataVault v2.0 will be developed to further streamline efficiencies, saving clients more time and money with the DV Donor App. DataVault v2.0 will also be developed for applications outside of Tamperloks including other Urine Drug Testing Cups as well as:
  - Illicit drug tests using saliva, hair, sweat and blood.
- Tracking, trace and management of:
  - Covid-19 immunisations.
  - Covid-19 rapid test kits.





# DATAVAULT DONOR APP

## SAFE WORKPLACE BEST PRACTICE

The DataVault Donor App is the link between mandatory workplace screening programs and the safe collection of the data. Pre-test registration, the use of QR Codes and observed self testing will increase test efficiency. The three level check system described is legally compliant, it will improve data accuracy and provide a safe workplace for medical officers by removing the risk of biohazard exposure.

There are three levels of participation which is defined as:


1. Donors – A worker or contractor who registers the App on their phone and is subject of the testing regime.
2. Testers – The medical officer at a site clinic, testing station or at a pre-employment medical centre (a third party participant)
3. Hosts – The employer responsible for fitness for work and infectious disease control in the workplace. The Host controls site access and sets the particulars of the testing regime.






# DATAVAULT DONOR APP WORK FLOW

## DONOR ENGAGEMENT & TESTER



### GAME CHANGER

✓ Only the Donor touches the Sample.




### GAME CHANGER

✓ The Tester can secure chain of custody without contact.




# DATAVAULT DONOR APP WORK FLOW

## HOST & THIRD PARTY ACCESS



### GAME CHANGER

- ✓ The Host can instantly request testing remotely to all Donors on or off site.



### GAME CHANGER

- ✓ The Data generates income, increases testing efficiency & creates savings.

# IT TEAM



01

▶ Neopharma Technologies CTO Gajendra Raj leads and manages the 14 person DataVault IT team who are based in Chennai, India.

02

▶ The team was engaged to develop DataVault and have since been appointed to further develop and support DataVault.

03

▶ Team members past experience includes: Amazon India, Uber, Interpol.



Neopharma Technologies Ltd was selected by Oracle last year to partner them via the Oracle for Startups Program which has commenced.

Oracles Business Development team did extensive due diligence on DataVault and saw great potential in a mutually beneficial partnership whereby DataVault is included in its suite of cloud-based programs available to its customers and sold by its sales team.

Oracle has predominantly large clients (Mining, Hospitals, Military, Manufacturing etc) that already do their periodic drug testing for its employees but do not have a centralized IT platform to manage the drug test programs and their test results.

Oracle has provided significant incentives for us to undertake this project. It also fits nicely as several large clients Neopharma has spoken to have also asked if we could integrate DataVault with their current Oracle Databases (the Bureau of Narcotics Indonesia, BNN being one).

Oracle Information:

[www.oracle.com](http://www.oracle.com)





Neopharma Technologies Ltd has recently executed a Letter of Intent (LOI) with German based company Apollo BioTech.

This LOI is for two prospective projects. Firstly, Apollo BioTech are trialing our TamperLoks DataVault solution with their key clients which include NATO military. Upon success of this trial Apollo BioTech will become the European Distributer for Neopharma's Drugs-of-Abuse testing solution.

While DataVault was initially developed with a focus on managing Drugs-of-Abuse testing programs, it is in essence an Enterprise Resource Management (ERM) platform for the secure collection, transfer and storage of drug test data. The platform can be readily modified to manage any type of Health Test Data including Covid-19 tests, Blood Testing, HIV testing, Dengue Fever testing etc.

Apollo BioTech represent one of the only few Covid-19 rapid Antigen tests that have been endorsed by the World Health Organisation (WHO) and also have direct relationship with them. Apollo BioTech see an opportunity for DataVault to be adapted to the tracking and tracing and identification of several WHO approved rapid tests, including Covid-19, HIV and Dengue Fever.

Apollo Biotech Information:

[www.apollo.bio](http://www.apollo.bio)



Neopharma Technologies Ltd has engaged MD Solutions as our exclusive distributor for Neopharma's Drugs-of-Abuse testing solution in Australasia.

MD Solutions has a large established network of clients across a range of industries in Australasia including Mining, Oil & Gas, Building & Construction, Logistics and Hospitals.

MD Solutions have also successfully managed the Australian TGA certification process for many other medical devices. MD Solutions were sufficiently impressed with Neopharma's Drugs-of-Abuse testing solution that they are both managing and paying for the TGA certification of the TamperLoks urine test cup. This is progressing and we expect to have final approval in Q3 of this year.

Once TGA certification has been issued for our testing solution, MD Solutions will be swapping out their existing drug testing cups that they are currently providing the Mining Industry in Australia through their strategic partners with Neopharma's Drugs-of-Abuse testing solution. MD Solutions through their strategic partnerships currently provide drug testing solutions to some of the largest mining organizations in Australia and we anticipate rolling out significant commercial orders in Q4 of this year.

MD Solutions information:

[www.mdsanz.com](http://www.mdsanz.com)



# COMPARABLE COMPANIES




Neopharma is a medical device hardware and multi purpose technology provider. Some comparable companies & their valuations are listed below:


As at 08/09/2021	Neopharma Technologies Ltd	Atomo Diagnostics Ltd ASX: ATI	Lumos Diagnostics Ltd ASX: LDX	OraSure Technologies, Inc NASDAQ: OSUR
Market Cap Undiluted	<b>\$6.73m</b>	\$125.00m	\$180.9m	\$804.34m
Industry	Healthcare & Technology	Healthcare & Technology	Healthcare & Technology	Healthcare & Technology
Snapshot	TamperLoks – hardware DataVault - software	Rapid blood testing diagnostics	Point of care diagnostics	Point of care diagnostics
Owner of technology and IP	Yes – hardware & software	Yes	Yes	Yes
Patents	Granted hardware patents globally	Yes	Filed	Yes

Source: ASX & NASDAQ 8th September 2021

# APPLICATION OF FUNDS



# SHAREHOLDER VALUE



# SUMMARY



- ✓ Award winning Medical device hardware and multi purpose technology provider.
- ✓ Intellectual property is unique and protected through granted patents and trademarks.
- ✓ Poised to capitalise on growing drugs-of-abuse markets.
- ✓ World class and leader in end-to-end drugs-of-abuse testing.
- ✓ Unparalleled reporting features.
- ✓ Manufacturing partner with ability to scale production quickly.
- ✓ Planning a major commercial rollout in the Australian Mining industry Q4 2021.
- ✓ Donor App Safe Workplace Industry Game Changer



# BOARD OF DIRECTORS



**Marcus L'Estrange**  
Executive Chairman

- Qualified Engineer with extensive commercial experience in venture capital, IT, mining, oil and gas and biomedical industries.
- Director of Raptor Global Corporation Ltd an established corporate advisory firm and major shareholder of Neopharma.
- Listed and reverse listed companies onto the ASX.
- Previous Director and Chairman of ASX listed companies and current director of unlisted public and private companies.
- Based in Perth Western Australia.


**Robert Martin**  
Non-Executive Director

- 40 years experience in the management and operation of commercial and resource projects.
- Director of ASX and unlisted companies in Australia.
- Major shareholder of Neopharma.
- Based in Perth Western Australia.

**Neel le Roux**  
Non-Executive Director


- Practising Specialist Clinical Psychologist, holder of a master's degree in Psychology.
- Past Director of the South African Police Psychology Unit in Kwazulu Natal, expertise in addictive disorders, trauma management and hostage negotiation.
- Based in Perth Western Australia.

# KEY PERSONNEL



**Gajendra Raj**  
CTO

- Pioneering technologist and experienced executive
- Expert in transforming business requirements into technical solutions, with a focus on quality, usability, security and scalability.
- Proven operator in IT infrastructure and security, architecture infrastructure design and full project life cycle management.
- Based in Kuala Lumpur, Malaysia and Chennai, India.



**Jason Yeun**  
Production Engineer

- Over 20 years experience as an Engineer, specialising in polymerics (plastics).
- Extensive commercial track record in 3-D modelling, identifying cost reductions and production efficiencies.
- Based in Kuala Lumpur and Penang, Malaysia.



**Shaun Melville**  
Sales & Marketing Manager

- Experienced private and public company director in Australia and overseas.
- Proven track record in sales and marketing in Health, IT and Financial Services.
- Director of Raptor Global Corporation Ltd an established corporate advisory firm and major shareholder of Neopharma Technologies.
- Listed and reverse listed companies onto the ASX.
- Based in Ho Chi Minh City Vietnam.

# DISCLAIMER



## NO INVESTMENT ADVICE

The information contained in this Information Memorandum is general information only and does not take into account the individual objectives, financial situation or needs of any particular person. Before investing, you should read this Information Memorandum carefully before making any decision to invest and consider the appropriateness of the information in this Information Memorandum having regard for your objectives, financial situation and needs.

## FORWARD LOOKING STATEMENTS

This Information Memorandum contains forward looking statements relating to future matters which are subject to known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Information Memorandum to be materially different from those expressed or implied by such statements.

## EXPERIENCED AND SOPHISTICATED INVESTORS ONLY

An investment in the company is only suitable for experienced and sophisticated investors with an awareness of the associated risks.




## CONTACT

### **Marcus L'Estrange**

Executive Chairman


 [marcus@neopharmatechnologies.com](mailto:marcus@neopharmatechnologies.com)

 +61 409 922 207

### **Shaun Melville**

Sales & Marketing Manager

 [shaun@neopharmatechnologies.com](mailto:shaun@neopharmatechnologies.com)

 +61 401 876 869

### **Neopharma Technologies Ltd**

ABN: 31 619 487 133

Level 4, 16 St Georges Terrace Perth WA 6000

[www.neopharmatechnologies.com](http://www.neopharmatechnologies.com)